BR112014020186A8 - Formulação de doxilamina e piridoxina e/ou seus metabólitos ou sais - Google Patents

Formulação de doxilamina e piridoxina e/ou seus metabólitos ou sais

Info

Publication number
BR112014020186A8
BR112014020186A8 BR112014020186A BR112014020186A BR112014020186A8 BR 112014020186 A8 BR112014020186 A8 BR 112014020186A8 BR 112014020186 A BR112014020186 A BR 112014020186A BR 112014020186 A BR112014020186 A BR 112014020186A BR 112014020186 A8 BR112014020186 A8 BR 112014020186A8
Authority
BR
Brazil
Prior art keywords
doxylamine
pyridoxine
formulation
composition
release component
Prior art date
Application number
BR112014020186A
Other languages
English (en)
Other versions
BR112014020186A2 (pt
Inventor
Vranderick Manon
St-Onge Jean-Luc
Gedeon Christelle
Gallo Michele
Gervais Éric
Original Assignee
Duchesnay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49004884&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014020186(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duchesnay Inc filed Critical Duchesnay Inc
Publication of BR112014020186A2 publication Critical patent/BR112014020186A2/pt
Publication of BR112014020186A8 publication Critical patent/BR112014020186A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Abstract

FORMULAÇÃO DE DOXILAMINA E PIRIDOXINA E/OU SEUS METABÓLITOS OU SAIS. Sistema de dosagem/forma farmacêutica oral de liberação dupla que inclui um componente/composição de liberação imediata e um componente/composição de liberação retardada é descrito. Cada um dos componentes/composição de liberação imediata e componente/composição de liberação retardada compreende um ou mais entre doxilamina, um análogo, um derivado, um pró-fármaco, um metabólito ou um sal e um ou mais entre piridoxina, um sal, um metabólito e/ou um sal de um metabólito. O sistema de dosagem/ forma farmacêutica oral de liberação dupla apresenta um perfil farmacocinético melhorado em relação à atual formulação de Diclectin(R) e é útil por exemplo para o alívio dos sintomas de náuseas e vômitos, por exemplo, no caso de náuseas e vômitos na gravidez (NVP).
BR112014020186A 2012-02-22 2013-02-18 Formulação de doxilamina e piridoxina e/ou seus metabólitos ou sais BR112014020186A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601754P 2012-02-22 2012-02-22
PCT/CA2013/050125 WO2013123595A1 (en) 2012-02-22 2013-02-18 Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Publications (2)

Publication Number Publication Date
BR112014020186A2 BR112014020186A2 (pt) 2017-06-20
BR112014020186A8 true BR112014020186A8 (pt) 2017-07-11

Family

ID=49004884

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014020186A BR112014020186A8 (pt) 2012-02-22 2013-02-18 Formulação de doxilamina e piridoxina e/ou seus metabólitos ou sais

Country Status (25)

Country Link
US (3) US9089489B2 (pt)
EP (2) EP2787971A4 (pt)
JP (2) JP5914701B2 (pt)
KR (1) KR101588259B1 (pt)
CN (1) CN104136004B (pt)
AR (2) AR090126A1 (pt)
AU (1) AU2013224598B2 (pt)
BR (1) BR112014020186A8 (pt)
CA (1) CA2848798C (pt)
CL (1) CL2014001828A1 (pt)
CY (1) CY1123122T1 (pt)
DK (1) DK3326611T3 (pt)
ES (1) ES2809713T3 (pt)
HK (1) HK1197035A1 (pt)
HU (1) HUE052301T2 (pt)
IL (1) IL233644A (pt)
LT (1) LT3326611T (pt)
MX (1) MX355912B (pt)
NZ (1) NZ627593A (pt)
PL (1) PL3326611T3 (pt)
PT (1) PT3326611T (pt)
SG (1) SG11201403931YA (pt)
TW (1) TWI638657B (pt)
UY (1) UY34631A (pt)
WO (1) WO2013123595A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2809713T3 (es) 2012-02-22 2021-03-05 Duchesnay Inc Formulación de doxilamina y piridoxina y/o metabolitos o sales de estas
JP6379194B2 (ja) 2013-07-22 2018-08-22 デュシネイ・インコーポレイテッド 悪心及び嘔吐の管理のための組成物
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting
CN103432126A (zh) * 2013-08-05 2013-12-11 北京阜康仁生物制药科技有限公司 一种治疗孕吐的药物组合物
JP6272561B2 (ja) * 2014-08-29 2018-01-31 デュシネイ・インコーポレイテッド ドキシラミン並びにピリドキシン及び／またはそれらの代謝産物もしくは塩の多峰性放出製剤
WO2017029573A1 (en) 2015-08-17 2017-02-23 Aequus Pharmaceuticals Inc. Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride
EP3697392B1 (en) 2017-10-17 2023-11-15 Synthon B.V. Tablets comprising tamsulosin and solifenacin
PL3628311T3 (pl) * 2018-09-27 2021-07-05 Inibsa Ginecologia, S.A. Sposób wytwarzania doustnej wielojednostkowej postaci dawkowanej bursztynianu doksylaminy i chlorowodorku pirydoksyny o zmodyfikowanym uwalnianiu
WO2022254277A1 (en) * 2021-05-31 2022-12-08 Maneesh Pharmaceuticals Ltd Extended release composition and its process for the preparation
AU2021225255B1 (en) * 2021-09-03 2022-06-16 Patel, Mihir MR Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting.

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
NZ242065A (en) 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US7744916B2 (en) 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
CA2366791A1 (en) 1999-04-06 2000-10-12 Kamal K. Midha Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second cns stimulant
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CA2350195C (en) * 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
WO2002055058A2 (en) 2001-01-09 2002-07-18 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7704542B2 (en) 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
AU2003303288B2 (en) 2002-08-16 2006-12-07 Microchips, Inc. Controlled release device and method
GB0229725D0 (en) 2002-12-19 2003-01-29 Univ Wales Medicine Haplotype partitioning and growth hormone SNPs
CA2577709C (en) 2004-09-01 2013-04-16 Microchips, Inc. Multi-cap reservoir devices for controlled release or exposure of reservoir contents
GB0502475D0 (en) * 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
JP5514547B2 (ja) 2007-09-14 2014-06-04 ロート製薬株式会社 眼科用組成物
KR101190708B1 (ko) * 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
AU2011236548A1 (en) * 2010-04-07 2012-11-01 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
KR20140007247A (ko) * 2010-06-22 2014-01-17 티더블유아이 파머수티컬스, 인코포레이티드 음식물 영향이 감소된 제어 방출 조성물
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
ES2809713T3 (es) 2012-02-22 2021-03-05 Duchesnay Inc Formulación de doxilamina y piridoxina y/o metabolitos o sales de estas
US9452181B2 (en) 2013-07-22 2016-09-27 Duchesnay Inc. Composition for the management of nausea and vomiting

Also Published As

Publication number Publication date
AR090126A1 (es) 2014-10-22
IL233644A0 (en) 2014-08-31
US20160374946A1 (en) 2016-12-29
EP2787971A1 (en) 2014-10-15
US20140314680A1 (en) 2014-10-23
CA2848798C (en) 2014-12-23
WO2013123595A1 (en) 2013-08-29
EP3326611A1 (en) 2018-05-30
MX355912B (es) 2018-05-04
SG11201403931YA (en) 2014-08-28
CY1123122T1 (el) 2021-10-29
NZ627593A (en) 2015-12-24
CN104136004A (zh) 2014-11-05
KR101588259B1 (ko) 2016-01-25
BR112014020186A2 (pt) 2017-06-20
CN104136004B (zh) 2018-03-06
US9937132B2 (en) 2018-04-10
MX2014008594A (es) 2015-03-03
US9089489B2 (en) 2015-07-28
AU2013224598A1 (en) 2014-07-31
CA2848798A1 (en) 2013-08-29
TWI638657B (zh) 2018-10-21
HUE052301T2 (hu) 2021-04-28
JP2016053092A (ja) 2016-04-14
EP2787971A4 (en) 2015-04-29
HK1197035A1 (en) 2015-01-02
US20150366808A1 (en) 2015-12-24
AU2013224598B2 (en) 2015-09-17
DK3326611T3 (da) 2020-08-17
PL3326611T3 (pl) 2020-11-02
CL2014001828A1 (es) 2014-11-14
TW201334780A (zh) 2013-09-01
JP2015508082A (ja) 2015-03-16
PT3326611T (pt) 2020-08-20
IL233644A (en) 2016-05-31
AR122580A2 (es) 2022-09-21
LT3326611T (lt) 2020-08-25
KR20140139496A (ko) 2014-12-05
JP5914701B2 (ja) 2016-05-11
US9375404B2 (en) 2016-06-28
ES2809713T3 (es) 2021-03-05
UY34631A (es) 2013-09-30
EP3326611B1 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
BR112014020186A8 (pt) Formulação de doxilamina e piridoxina e/ou seus metabólitos ou sais
BR112018002585A2 (pt) 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amina para uso no tratamento de câncer
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
BR112012008317A2 (pt) produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
BR112015021002B8 (pt) Forma de dosagem sólida farmacêutica compreendendo um ingrediente farmacêutico ativo
CR20110110A (es) Composicion farmaceutica
CR20120476A (es) Formulaciones orales y sales lipofílicas de metilnaltrexona
BR112016002459A2 (pt) Derivados de benzimidazolil-metil ureia como agonistas receptores de alx
BR112013004016A2 (pt) formulações á base de nalbufina e as respectivas utilizações
BR112015011430A2 (pt) composição para liberação imediata e prolongada
CL2015000732A1 (es) Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
BR112015019587A2 (pt) combinações compreendendo compostos maba e corticosteroides
BR112015024938A2 (pt) formulação, uso de formulações, e, processo para preparação de formulações
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
BR112015011515A2 (pt) Composições farmacêuticas de inibidores de cetp
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
BR112017009521A2 (pt) comprimido de múltiplas camadas que contém um fármaco instável à luz
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
BR112014028121A2 (pt) n-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
BR112015021480A2 (pt) soluções de hidromorfona intratecais tendo estabi-lidade melhorada
BR112013018781A2 (pt) composto derivado de piridona, e, composição farmacêutica
BR112016009214A8 (pt) uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]